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Abstract
Background:
Oocyte donation pregnancies- non-disclosure of oocyte recipient (OR) status to obstetric care
providers and perinatal outcomes.Many studies report a higher rate of pregnancy-induced
hypertension (PIH) and severe pre-eclampsia (PET) in OR pregnancies. The objective is to
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determine the rates of non-disclosure of OR pregnancy to obstetric care providers and also the
rates of perinatal complications.
Method:
This was a retrospective review of all oocyte recipient (OR) pregnancies, who subsequently
delivered at Cork University Maternity Hospital, between 2007- 2012 inclusive. Obstetric case
notes were reviewed to investigate perinatal outcomes and whether OR status had been
documented (unambiguously, in code or not at all).
Results
Less than one-third (30.2%; n=32/106) had unambiguous documentation, one-third (33%;
n=35/106) had no documentation and the remainder (36.8%; n=39/106) had a code familiar only
to their obstetrician. There was a high rate of gestational hypertensive disorders (28.3%; n= 30),
most frequently occurring with multiple gestation.
Conclusion
There was a low rate of clear documentation of OR status. Gestational hypertensive disorders
occurred with increased frequency.
Introduction
Oocyte donation (OD), since its introduction 30 years ago, has become an increasingly common solution to
involuntary childlessness. Initially, it was used to enable women with premature ovarian failure to conceive .
Increasingly, it is recommended to women of advanced reproductive age and to those with intractably poor embryo
quality . The most recent European data continues to demonstrate a year on year rise in the number of OD cycles.
Between 2011 and 2012 there was a 10% rise in the number of OD cycles, and a 28.2% increase on the previous
year . The vast majority of Irish couples travel abroad for oocyte donation treatment, most frequently to Spain and
the Czech Republic; a tiny minority undergo treatment in Ireland using an altruistic donor. Couples undergoing
oocyte donation treatment are counselled to inform their child about his/her donor conception.  However, in
pregnancy, many couples are undecided or do not wish to inform the child and therefore do not wish to disclose their
OR status to obstetric care providers. OR pregnancies have a higher incidence of pregnancy complications-
particularly hypertension . Non-disclosure of OR status makes it difficult to identify these higher-risk pregnancies,
target antenatal care appropriately and may inflate the incidence of complications in OR pregnancies. The objective
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of this study was to establish the proportion of women who disclose the origin of their pregnancy to their obstetric
care provider and the true rate of complications.
Methods
All OR pregnancies were retrospectively identified from the patient database at Cork Fertility and those that
delivered at Cork University Maternity Hospital (8,500 births annually with public and private maternity care
delivered in a single unit), during the period January 2007- December 2012, were included. Those who delivered
elsewhere were excluded. Oocyte donation treatment with both known and anonymous donors is carried out at Cork
Fertility as well as medical support for women who undergo oocyte donation treatment in other clinics. The fertility
charts of the study population were reviewed. Obstetric charts were reviewed for documentation of OR status:
unambiguous documentation (OR status clearly documented in writing), coded identification (OR status identifiable
through a subtle, non-standardised coding system, familiar only to the obstetrician) and no documentation.
Obstetric medical records were reviewed to identify the rate of maternal complications. Specifically, gestational
hypertensive disorders, either pre-eclampsia (defined as persistent blood pressure of ≥ 140/90mmHg after 20 weeks’
gestation with associated proteinuria >300mg/24 hours) or pregnancy-induced hypertension (persistent blood
pressure readings ≥ 140/90mmHg, without associated proteinuria, occurring after 20 weeks’ gestation), gestational
diabetes mellitus and obstetric cholestasis. The gestation, onset of labour and mode of delivery, were recorded. The
rates of maternal complications were assessed according to age ranges: 45 years or older, 40-44 years, 35-39 years
and less than 35 years. These were further divided according to parity. The data was also compared to that of the
general hospital population . In this study, we report descriptive statistics on maternal characteristics, clinical
practice, maternal and perinatal outcome using SPSS (IBM SPSS Statistics version 20).
Results
One hundred and six OR pregnancies (101 women) were identified. Five women had two pregnancies conceived
with donated oocytes. Twenty OR pregnancies were excluded as they delivered at other institutions. There were 75
singleton pregnancies, 22 twin pregnancies and 9 triplet pregnancies.
Maternal Demographics
The mean age was 40.5 years (± 4.8 years, range 28-49 years). Sixty-five percent (65.1%; n=69) were nulliparous,
17 had a previous live birth following a spontaneous conception and 9 had a live birth following other assisted
reproductive technologies using autologous oocytes. (Table 1)
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Disclosure of oocyte recipient status
Thirty percent (30.2%; n=32/106) had unambiguous documentation of OR status in their obstetric case notes. A
further 36.8% (39/106) had coded identification. Coding included underlining the first two letters of the abbreviation
‘E.D.D.’ (‘estimated date of delivery’) or writing the abbreviations ‘DE’ (‘donor egg’) or ‘ED’ (‘egg donation’)
discreetly in the obstetric records. (Table 1). One third (33%; 35/106) had no form of documentation of OR status.
Of this group, 27 had ‘IVF treatment’ documented and the remainder (n=9) had no documentation of any assisted
conception. There were no differences in rates of disclosure according to plurality (p=.493). Similarly, there were no
significant differences in rates of disclosure according to age profile, however those less than 35 years had a low rate
(18.8%) of having no documentation of OR status. This age group had the highest proportion of infertility due to
premature ovarian failure (56%). Women attending for private obstetric care were more likely to have coded
documentation (p <0.05). (Table 1)
Mode of Delivery
There was a high rate of caesarean delivery (77%) compared with that of the general hospital population (28.2%
between 2009 - 2012) . Elective caesarean section (CS) was the most frequent mode of delivery (41.5%; n= 44/106)
with only 22.6% (n=24/106) having a vaginal delivery. As expected, multiple pregnancies had a high rate of CS
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delivery with all triplets delivered by CS (55.6% emergency CS and 44.4% elective CS) and 86.4% of twin
pregnancies delivered by CS. However, singletons also had a high caesarean delivery rate of 72% (n= 54/75) with
elective CS more frequent (55.5%; n= 30/54).
Maternal Complications
Gestational hypertension was the most frequently diagnosed maternal complication, occurring in almost one-third
(28.3%; n=30). Both PET and PIH occurred with equal frequency. (Table 2) Both PET and Gestational Diabetes
occurred at a significantly higher rate than that of the general hospital population (14.2; n=15/106 v 1.4 %; n=
495/34490 and 3.7% n= 4/106 v 1.2%; n= 423/34490 respectively) . Only one-quarter of all women who developed
gestational hypertensive disorders had unambiguous documentation of OR status. (Table 2)
Consistent with the generally accepted increased risk profile associated with nulliparous pregnancies, all recorded
complications occurred with increased frequency amongst this parity group, across all age ranges. Gestational
hypertension (PET and PIH) occurred most frequently in nulliparous women but their distribution across age ranges
varied (35.7%- 55.5%). Over half (55.5%; n= 5/22) of nulliparous women aged 45 years or older had gestational
hypertension in pregnancy and this group had the highest rate of pregnancy-induced hypertension (44.4%; n= 4/22).
However, it was the nulliparous women less than 35 years old who had the highest rate of pre-eclampsia (28.6%; n=
4/14). Adjustment for plurality, age and parity indicates that multiple gestation is significantly associated with
gestational hypertensive disorders (OR 3.9 95% CI 1.5-9.8) (Table 3)
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According to the recommendations from National Institute for Health and Care Excellence regarding hypertension
in pregnancy, aspirin is advised from 12 weeks’ gestation in the presence of two or more moderate risk factors
which include; first pregnancy, age ≥ 40 years old and multiple pregnancy . Less than one third (31.4% n= 16/51) of
the women with two or more of these risk factors were appropriately prescribed aspirin. The rate was highest
amongst the multiple pregnancy group (42.8%; n= 12/28) and only 17.4% (n= 4/23) amongst at-risk singleton
pregnancies. During the study period, there was one case of severe life-threatening pre-eclampsia. In this case there
was no documentation of either donor oocyte or assisted conception. The 35 year old nullipara with diminished
ovarian reserve, presented at 18 weeks’ gestation with acute PET. She developed severe HELLP syndrome and an
associated liver laceration, requiring laparotomy and hysterotomy to deliver the fetus .
Perinatal Outcomes
The rate of preterm delivery (<37 weeks’ gestation) amongst singleton pregnancies was 13.3% (n= 10/74; range
28 - 36  weeks’ gestation) and 59.1% (n=13/22; range 33 -36 ) amongst twins. The gestational age range of
triplet deliveries was 28 - 35 . All preterm infants were delivered by CS. Of 144 live born infants, one third
(33.3%; n=48/144) were admitted to NICU, with multiples accounting for 82% of those admissions (27 infants of
triplet pregnancies and 9 infants of twin pregnancies). One quarter of the pregnancies (25.4%, n= 27/106) resulted in
neonatal admission to the NICU. All triplets (n=27 infants) were admitted to NICU for reasons of prematurity and
low birth weight. Twenty-seven percent (27.3%; n= 6/22 twin pairs; 9/44 infants) of twins had one or both infant
requiring NICU admission. Of live born singletons, 16.4% (n= 12/73) were admitted with prematurity (n=4), RDS
(n=4) and jaundice (n=4) the most frequent reasons for admission. One intrauterine death, that of a karyotypically
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normal male infant with absent corpus callosum, occurred amongst the study group.
Discussion
This study highlights a low rate of clear documentation of OR status in 106 oocyte recipient pregnancies, one-third
of which were complicated by gestational hypertensive disorders. Gestational Diabetes (GDM) occurred with
increased frequency compared with the general hospital population. The strength of this study is that it is the first to
report on rates of non- disclosure of oocyte recipient status to the obstetric care provider. It is particularly relevant in
those jurisdictions where egg donation is not legally or readily available, requiring prospective oocyte recipients to
travel abroad for treatment. The recently enacted Children and Family Relationships Bill in Ireland contains
legislation relating to donor conception . This legislation prohibits the use of anonymous egg donation in the
country. However, it is accepted that anonymous egg donation treatment abroad, where, commonly, anonymity is
mandatory, will not be prohibited by the Act. This means that large numbers of Irish couples will continue to have
anonymous egg donation treatment abroad and many will continue to conceal the status of their pregnancies to their
obstetric care providers.
We are aware of the limitations of our study particularly the inability to obtain a suitable control group, conceiving
with autologous oocytes, matched for age and parity. Data was not available on the general population in terms of
age and parity to compare incidence of complications. From this study, we were unable to distinguish if it is request
by patients or suggestion by the obstetrician that led to non-disclosure or coded documentation in obstetric records.
This important distinction warrants further investigation as it would allow insight into the extent of patient comfort
with disclosure and associated concerns regarding confidentiality.
Almost one-third of OR pregnancies were complicated by gestational hypertension and the rates of PIH in particular
are similar to those reported in previous studies . Nulliparity and maternal age 45 years or above accounted for
the highest proportion of women with PIH. However, nulliparas less than 35 years of age had the highest incidence
of pre-eclampsia. Studies by Levron et al and Keegan et al had similar findings, where young oocyte recipients had
the higher rate of pregnancy-induced hypertension and pre-eclampsia when compared to IVF patients conceiving
with autologous oocytes. They suggest the possibility of a causal link between the pathophysiology of early loss of
ovarian function and the development of PIH, which could warrant further investigation . Although our numbers
are small, thus limiting interpretation of the data, all cases of GDM in the study group occurred in women aged 35
years or more, which is consistent with the link between advanced maternal age and increased prevalence of GDM
. There was one case of early-onset, life threatening pre-eclampsia with an associated late miscarriage where there
was no documentation of OR status. There are several similar reports in the literature including one by Pecks et al of
severe life-threatening pre-eclampsia in OR pregnancies .
The low rate of disclosure and clear documentation limits the obstetric team in the delivery of appropriate antenatal
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surveillance. Furthermore, opportunities for appropriate intervention, such as the prescribing of aspirin, are missed.
The low rates of disclosure and clear documentation of OR pregnancies should be addressed in a sensitive way in
order to maintain confidentiality while allowing the obstetric care provider to optimise antenatal surveillance in this
higher-risk pregnancy group.
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